Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online August 1, 2023.
Article Versions
- You are currently viewing a Latest version of this article (August 1, 2023 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2023 The Journal of Rheumatology
Author Information
- Glen S. Hazlewood,
- Pooneh Akhavan,
- Jordi Pardo Pardo,
- Arnav Agarwal,
- Orit Schieir,
- Claire E.H. Barber,
- Laurie Proulx,
- Dawn P. Richards,
- Claire Bombardier,
- Janet E. Pope,
- Cheryl Barnabe,
- Peter Tugwell,
- Shahin Jamal,
- J. Carter Thorne,
- Roko P.A. Nikolic,
- Majed Khraishi,
- Nick Bansback,
- Alexandra Legge,
- Vivian Bykerk and
- Regina Taylor-Gjevre
- Glen S. Hazlewood, MD, PhD, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Arthritis Research Canada, Vancouver, British Columbia, Canada.
- Pooneh Akhavan, MD, MSc, Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada.
- Jordi Pardo Pardo, LDO, Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada.
- Arnav Agarwal, MD, Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada; MAGIC Evidence Ecosystem Foundation, Oslo, Norway.
- Orit Schieir, PhD, Canadian Early Arthritis Cohort Study, Toronto, Ontario, Canada.
- Claire E.H. Barber, MD, PhD, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Arthritis Research Canada, Vancouver, British Columbia, Canada.
- Laurie Proulx, B.Com, Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada.
- Dawn P. Richards, PhD, Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada.
- Claire Bombardier, MD, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Janet E. Pope, MD, MPH, Department of Medicine, Western University, Schulich School of Medicine &Dentistry, London, Ontario, Canada.
- Cheryl Barnabe, MD, MSc, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Arthritis Research Canada, Vancouver, British Columbia, Canada.
- Peter Tugwell, MD, Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
- Shahin Jamal, MD, MSc, Division of Rheumatology, University of British Columbia,Arthritis Research Canada, Vancouver, British Columbia, Canada.
- J. Carter Thorne, MD, The Arthritis Program Research Group, Newmarket, Ontario, Canada.
- Roko P.A. Nikolic, MD, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Majed Khraish, MD, Department of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
- Nick Bansback, PhD, Arthritis Research Canada, Vancouver, British Columbia, Canada;School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
- Alexandra Legge, MD, MSc, Arthritis Research Canada, Vancouver, British Columbia, Canada;Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
- Vivian Bykerk, MD, Hospital for Special Surgery, Weill Cornell Medicine (Cornell University), New York, New York, USA.
- Regina Taylor-Gjevre, MD, MSc, Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan, Saskatchewan, Manitoba, Canada.
-
Funding for this guideline was provided by the Canadian Rheumatology Association.
PA received honoraria for advisory boards from Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, and Roche. JPP received funding from the CRA to Cochrane Musculoskeletal to provide methodological support for guideline development. LP and DPR are Volunteer Vice Presidents of Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharmaceutical companies. C. Bombardier received consulting fees from Samsung Bioepis and GSK.; and is a member of the advisory boards for Merck and BGP Pharma (a Mylan co). JEP received consulting fees from AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, and VIatris. C. Barnabe received honoraria for advisory boards (Celltrion Healthcare) and speaker fees (Pfizer, Janssen, Fresenius Kabi). SJ received consulting fees from AbbVie, Amgen, Biojamp, Celltrion, Eli Lilly, Fresenius Kabi, GSK, Janssen, Merck, Pfizer, Sandoz, Teva, and UCB. JCT received consulting fees from AbbVie, Biogen, Celgene, Merck, Pfizer, Roche, and Sandoz. MK received consulting fees from Amgen, AbbVie, Celgene, Merck, Novartis, Pfizer, and Gilead. VB received consulting fees from AbbVie, ER Squibb & Sons, Janssen, and Pfizer. The remaining authors declare no conflicts of interest relevant to this article.
- Address correspondence to Dr. G.S. Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada. Email: gshazlew@ucalgary.ca.